RxDoctor Payments Data

Deon Edgerson George

Internal Medicine · Chester, MDNPI 1508033929

Payments from drug & device makers

$615in general payments, 2019–2025

Across 29 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$134
  • AbbVie$67
  • Exact Sciences$61
  • Irhythm Technologies, Inc.$55
  • Novo Nordisk$45
  • Abbott$44
  • plus $208 from 8 others

What the payments were for

  • Food & beverage$615100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$615 in reported general payments places this provider in the 65th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$185,221
Medicare patients
432
Services billed
2,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$164,044
TrulicityDulaglutide28$40,473
JardianceEmpagliflozin31$38,036
EliquisApixaban28$37,448
JanuviaSitagliptin Phosphate24$31,467
LinzessLinaclotide13$19,784
Tresiba Flextouch U-200Insulin Degludec16$16,865
MyrbetriqMirabegron13$15,806
XareltoRivaroxaban11$11,634
Rosuvastatin Calcium304$8,693
Atorvastatin Calcium401$7,044
Spiriva RespimatTiotropium Bromide12$6,045
Doxepin Hcl27$4,477
Diclofenac Sodium15$4,005
Wixela InhubFluticasone Propion/Salmeterol12$3,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$45$164,04491 claims
Lilly USA, LLCTrulicity$19$40,47328 claims
PfizerEliquis$134$37,44828 claims
MerckJanuvia$32$31,46724 claims
AbbVieLinzess, Synthroid$67$21,77852 claims
Astellas Pharma US IncMyrbetriq$26$15,80613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Chester

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →